ONCOLYTIC PREPARATION

Cancer virotherapy is a new and promising approach to treating malignant diseases. The first medicines of this kind, intended for a limited number of cancer diagnoses, are only now entering the market. Most development strategies focus on genetically modified oncolytic viruses, which require extensive safety testing before use. However, some naturally occurring viruses from our environment also demonstrate strong oncolytic potential, especially when applied in innovative ways. 

Within the project, we will develop a prototype of an oncolytic preparation based on the natural vesicular stomatitis virus, which scientific studies have shown to possess antitumor activity. The product will be designed in line with good manufacturing practice principles, with verified process reproducibility and ensured genetic stability. Finally, we will prepare a development and commercialization strategy to advance this oncolytic virus towards becoming a candidate for clinical trials. 

The project (NPOO.C3.2.R3-I1.02.0045) is funded by a grant from European Union funds under the Recovery and Resilience Mechanism, with a total value of EUR 199,753.48.